Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population

References

• Key Statistics for Prostate Cancer. American Cancer Society; 2019 [accessed 2019 Mar 26]. Available from: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. Version 4.2018. National Comprehensive Cancer Network; 2018 Aug 15 [accessed 2018 Oct 1]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
   Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
   PubMed Web of Science ®Google Scholar
• Wadosky KM, Koochekpour S. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget. 2016;7(39):64447–64470.
   PubMedGoogle Scholar
• Nevedomskaya E, Baumgart SJ, Haendler B. Recent advances in prostate cancer treatment and drug discovery. Int J Mol Sci. 2018;19(5):1359.
   Web of Science ®Google Scholar
• Thoreson GR, Gayed BA, Chung PH, et al. Emerging therapies in castration resistant prostate cancer. Can J Urol. 2014;21(2 Supp 1):98–105.
   PubMedGoogle Scholar
• FDA approves apalutamide for non-metastatic castration-resistant prostate cancer. Silver Spring (MD): U.S. Food & Drug Administration [updated 2018 May 3; accessed 2018 Oct 1]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm596796.htm
   Google Scholar
• FDA approves enzalutamide for castration-resistant prostate cancer. Silver Spring (MD): U.S. Food & Drug Administration [updated 2018 Jul 16; accessed 2018 Oct 10]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm613543.htm
   Google Scholar
• FDA approves darolutamide for non-metastatic castration-resistant prostate cancer. Silver Spring (MD): U.S. Food & Drug Administration [updated 2019 Jul 30; accessed 2019 Sep 26]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer
   Google Scholar
• Yong C, Onukwugha E, Mullins CD, et al. The use of health services among elderly patients with stage IV prostate cancer in the initial period following diagnosis. J Geriatr Oncol. 2014;5(3):290–298.
   PubMed Web of Science ®Google Scholar
• Seal B, Sullivan SD, Ramsey SD, et al. Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases. Appl Health Econ Health Policy. 2014;12(5):547–557.
   PubMedGoogle Scholar
• Alemayehu B, Buysman E, Parry D, et al. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and medicare advantage US patient population. J Med Econ. 2010;13(2):351–361.
   PubMedGoogle Scholar
• Mehra M, Wu Y, Dhawan R. Healthcare resource use in advanced prostate cancer patients treated with docetaxel. J Med Econ. 2012;15(5):836–843.
   PubMedGoogle Scholar
• Sammon JD, McKay RR, Kim SP, et al. Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. Urology. 2015;85(2):343–349.
   PubMed Web of Science ®Google Scholar
• Grochtdreis T, Konig HH, Dobruschkin A, et al. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. PLoS One. 2018;13(12):e0208063.
   PubMed Web of Science ®Google Scholar
• Li T, Shore N, Mehra M, et al. Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease. Cancer. 2017;123(18):3591–3601.
   PubMed Web of Science ®Google Scholar
• Valderrama A, Tangirala K, Babajanyan S, et al. Treatment, healthcare resource utilization, and costs associated with non-metastatic and metastatic castration-resistant prostate cancer: A claims analysis. J Clin Oncol. 2017;35(15_suppl):e18341.
   Google Scholar
• Schultz NM, Flanders SC, Wilson S, et al. Treatment duration, healthcare resource utilization, and costs among chemotherapy-naïve patients with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate: A retrospective claims analysis. Adv Ther. 2018;35(10):1639–1655.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Potluri RC, Ng Y, et al. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med. 2016;5(2):182–191.
   PubMed Web of Science ®Google Scholar
• Moreira DM, Howard LE, Sourbeer KN, et al. Predictors of time to metastasis in castration-resistant prostate cancer. Urology. 2016;96:171–176.
   PubMed Web of Science ®Google Scholar
• Saad F, Ivanescu C, Phung D, et al. Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials. Prostate Cancer Prostatic Dis. 2017;20(1):110–116.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. Version 1.2019. 2019 Mar 6 [accessed 2018 Oct 1]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
   Google Scholar
• Smith MR, Saad F, Chowdhury S, SPARTAN Investigators, et al. Apalutamide treatment of metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–1418.
   PubMed Web of Science ®Google Scholar
• Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–2474.
   PubMed Web of Science ®Google Scholar
• Attard G, Saad F, Tombal BF, et al. Health-related quality of life (HRQoL) deterioration and pain progression in men with non-metastatic castration-resistant prostate cancer (M0 CRPC): results from the PROSPER study. Presented at the American Society of Clinical Oncology Annual Meeting. Chicago, IL, June 1–5, 2018.
   Google Scholar
• Saad F, Cella D, Basch E, et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(10):1404–1416.
   PubMed Web of Science ®Google Scholar